Cargando…

Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study

BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Oertel, Frederike C., Outteryck, Olivier, Knier, Benjamin, Zimmermann, Hanna, Borisow, Nadja, Bellmann-Strobl, Judith, Blaschek, Astrid, Jarius, Sven, Reindl, Markus, Ruprecht, Klemens, Meinl, Edgar, Hohlfeld, Reinhard, Paul, Friedemann, Brandt, Alexander U., Kümpfel, Tania, Havla, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657100/
https://www.ncbi.nlm.nih.gov/pubmed/31345223
http://dx.doi.org/10.1186/s12974-019-1521-5
_version_ 1783438744339087360
author Oertel, Frederike C.
Outteryck, Olivier
Knier, Benjamin
Zimmermann, Hanna
Borisow, Nadja
Bellmann-Strobl, Judith
Blaschek, Astrid
Jarius, Sven
Reindl, Markus
Ruprecht, Klemens
Meinl, Edgar
Hohlfeld, Reinhard
Paul, Friedemann
Brandt, Alexander U.
Kümpfel, Tania
Havla, Joachim
author_facet Oertel, Frederike C.
Outteryck, Olivier
Knier, Benjamin
Zimmermann, Hanna
Borisow, Nadja
Bellmann-Strobl, Judith
Blaschek, Astrid
Jarius, Sven
Reindl, Markus
Ruprecht, Klemens
Meinl, Edgar
Hohlfeld, Reinhard
Paul, Friedemann
Brandt, Alexander U.
Kümpfel, Tania
Havla, Joachim
author_sort Oertel, Frederike C.
collection PubMed
description BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients. METHODS: We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0–2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group’s eyes included 18 eyes without (Eye(ON-)) and 20 eyes with history of ON (Eye(ON+)). Using spectral domain optical coherence tomography (OCT), we acquired peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIP), inner nuclear layer (INL), and macular volume (MV). High-contrast visual acuity (VA) was assessed at baseline. RESULTS: At baseline in Eye(ON-), pRNFL (94.3 ± 15.9 μm, p = 0.36), INL (0.26 ± 0.03 mm(3), p = 0.11), and MV (2.34 ± 0.11 mm(3), p = 0.29) were not reduced compared to HC; GCIP showed thinning (0.57 ± 0.07 mm(3); p = 0.008), and VA was reduced (logMAR 0.05 ± 0.15 vs. − 0.09 ± 0.14, p = 0.008) in comparison to HC. Longitudinally, we observed pRNFL thinning in models including all patient eyes (annual reduction − 2.20 ± 4.29 μm vs. − 0.35 ± 1.17 μm, p = 0.009) in comparison to HC. Twelve Eye(ON-) with other than ipsilateral ON attacks ≤ 6 months before baseline showed thicker pRNFL at baseline and more severe pRNFL thinning in comparison to 6 Eye(ON-) without other clinical relapses. CONCLUSIONS: We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye(ON-) with other than ipsilateral ON attacks within 6 months before baseline. One possible interpretation could be a reduction of the swelling, which could mean that MOG-IgG patients show immune-related swelling in the CNS also outside of an attack’s target area. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1521-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6657100
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66571002019-07-31 Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study Oertel, Frederike C. Outteryck, Olivier Knier, Benjamin Zimmermann, Hanna Borisow, Nadja Bellmann-Strobl, Judith Blaschek, Astrid Jarius, Sven Reindl, Markus Ruprecht, Klemens Meinl, Edgar Hohlfeld, Reinhard Paul, Friedemann Brandt, Alexander U. Kümpfel, Tania Havla, Joachim J Neuroinflammation Research BACKGROUND: Serum antibodies against myelin-oligodendrocyte-glycoprotein (MOG-IgG) are detectable in a proportion of patients with acute or relapsing neuroinflammation. It is unclear, if neuro-axonal damage occurs only in an attack-dependent manner or also progressively. Therefore, this study aimed to investigate longitudinally intra-retinal layer changes in eyes without new optic neuritis (ON) in MOG-IgG-seropositive patients. METHODS: We included 38 eyes of 24 patients without ON during follow-up (F/U) [median years (IQR)] 1.9 (1.0–2.2) and 56 eyes of 28 age- and sex-matched healthy controls (HC). The patient group’s eyes included 18 eyes without (Eye(ON-)) and 20 eyes with history of ON (Eye(ON+)). Using spectral domain optical coherence tomography (OCT), we acquired peripapillary retinal nerve fiber layer thickness (pRNFL) and volumes of combined ganglion cell and inner plexiform layer (GCIP), inner nuclear layer (INL), and macular volume (MV). High-contrast visual acuity (VA) was assessed at baseline. RESULTS: At baseline in Eye(ON-), pRNFL (94.3 ± 15.9 μm, p = 0.36), INL (0.26 ± 0.03 mm(3), p = 0.11), and MV (2.34 ± 0.11 mm(3), p = 0.29) were not reduced compared to HC; GCIP showed thinning (0.57 ± 0.07 mm(3); p = 0.008), and VA was reduced (logMAR 0.05 ± 0.15 vs. − 0.09 ± 0.14, p = 0.008) in comparison to HC. Longitudinally, we observed pRNFL thinning in models including all patient eyes (annual reduction − 2.20 ± 4.29 μm vs. − 0.35 ± 1.17 μm, p = 0.009) in comparison to HC. Twelve Eye(ON-) with other than ipsilateral ON attacks ≤ 6 months before baseline showed thicker pRNFL at baseline and more severe pRNFL thinning in comparison to 6 Eye(ON-) without other clinical relapses. CONCLUSIONS: We observed pRNFL thinning in patients with MOG-IgG during F/U, which was not accompanied by progressive GCIP reduction. This effect could be caused by a small number of Eye(ON-) with other than ipsilateral ON attacks within 6 months before baseline. One possible interpretation could be a reduction of the swelling, which could mean that MOG-IgG patients show immune-related swelling in the CNS also outside of an attack’s target area. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12974-019-1521-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-25 /pmc/articles/PMC6657100/ /pubmed/31345223 http://dx.doi.org/10.1186/s12974-019-1521-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Oertel, Frederike C.
Outteryck, Olivier
Knier, Benjamin
Zimmermann, Hanna
Borisow, Nadja
Bellmann-Strobl, Judith
Blaschek, Astrid
Jarius, Sven
Reindl, Markus
Ruprecht, Klemens
Meinl, Edgar
Hohlfeld, Reinhard
Paul, Friedemann
Brandt, Alexander U.
Kümpfel, Tania
Havla, Joachim
Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title_full Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title_fullStr Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title_full_unstemmed Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title_short Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
title_sort optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657100/
https://www.ncbi.nlm.nih.gov/pubmed/31345223
http://dx.doi.org/10.1186/s12974-019-1521-5
work_keys_str_mv AT oertelfrederikec opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT outteryckolivier opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT knierbenjamin opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT zimmermannhanna opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT borisownadja opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT bellmannstrobljudith opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT blaschekastrid opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT jariussven opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT reindlmarkus opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT ruprechtklemens opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT meinledgar opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT hohlfeldreinhard opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT paulfriedemann opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT brandtalexanderu opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT kumpfeltania opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy
AT havlajoachim opticalcoherencetomographyinmyelinoligodendrocyteglycoproteinantibodyseropositivepatientsalongitudinalstudy